iShares Genomics Immnlgy & Hlthcr ETF holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
iShares Genomics Immunology and Healthcare ETF IDNA
Morningstar’s Analysis IDNA
Will IDNA outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the IDNA management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of IDNA’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Revolution Medicines Inc Ordinary Shares | 7.07 | 11M | Healthcare |
Moderna Inc | 6.49 | 10M | Healthcare |
Ipsen SA | 4.93 | 8M | Healthcare |
Merck & Co Inc | 4.67 | 7M | Healthcare |
Exelixis Inc | 4.63 | 7M | Healthcare |
Twist Bioscience Corp | 4.53 | 7M | Healthcare |
Takeda Pharmaceutical Co Ltd | 4.34 | 7M | Healthcare |
GSK PLC | 4.18 | 7M | Healthcare |
Bayer AG | 4.11 | 6M | Healthcare |
Roche Holding AG Ordinary Shares new | 4.10 | 6M | Healthcare |
United States